Men's Health After 40: The GLP-1, Testosterone, and Cancer Risk Data

Testosterone decline, rising cancer risk, cardiovascular concerns, and biological aging. The 2026 data on how GLP-1 medications address all four simultaneously.

June 19, 2026

After 40, men's health starts pulling in multiple directions at once. Testosterone declines roughly 1–2% per year. Cancer risk begins its steady climb. Cardiovascular disease becomes the leading cause of death. And the metabolic effects of decades of eating and activity habits accumulate in ways that accelerate aging.

What's remarkable about the 2026 research landscape is how many of these age-related threats GLP-1 medications appear to address simultaneously. Not as a miracle drug — as a metabolic intervention that treats the root dysfunction driving multiple downstream problems.

Testosterone After 40: The ENDO 2026 Data

Age-related testosterone decline is real, but it's often exaggerated and confused with obesity-related low T. A healthy-weight 45-year-old man will have lower testosterone than his 25-year-old self, but usually still within normal range. A 45-year-old man carrying 40+ extra pounds of body fat, however, often has clinically low testosterone — not because of aging, but because of adiposity-driven aromatase activity.

ENDO 2026 data showed that men with obesity who lost 10% body weight on GLP-1 medications experienced a 53–77% increase in testosterone levels, with preservation of the HPG axis and improved sperm quality. For the millions of men over 40 whose "low T" is actually "high body fat," this is a fundamentally different treatment pathway than jumping straight to TRT.

Cancer Risk: The ASCO 2026 Data

A study published in Annals of Oncology and presented at ASCO 2026 analyzed over 229,000 patients and found that GLP-1 users had a 41% lower incidence of obesity-related cancers compared to those receiving only diet and exercise counseling. The reductions were even more dramatic for specific cancer types:

For men over 40, the relevance is direct: colorectal cancer screening begins at 45, prostate cancer risk rises steadily after 50, and metabolic-syndrome-driven cancers become a genuine concern. If GLP-1 medications reduce the metabolic environment that promotes cancer growth — even before they're studied as cancer prevention drugs specifically — that's a meaningful addition to any man's health strategy.

Cardiovascular Protection: The SELECT Trial Baseline

The SELECT trial — the landmark cardiovascular outcomes trial for semaglutide in non-diabetic obesity — demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients with obesity and established cardiovascular disease. This led to semaglutide receiving an FDA indication for cardiovascular risk reduction in 2024.

For men over 40, cardiovascular disease is the number one killer. The SELECT data means that semaglutide isn't just treating your weight — it's actively protecting your heart and brain against the events most likely to end your life prematurely.

Biological Aging: The UC San Diego Data

The UC San Diego study published in Nature Communications in May 2026 found that semaglutide slowed biological aging by 9% on the DunedinPACE epigenetic clock, with additional improvements across clocks linked to inflammation, brain health, cardiovascular function, and metabolic health. While preliminary, this adds a longevity dimension that's particularly relevant for men 40+ who are beginning to think about healthspan — not just how long they live, but how well they live.

The Comprehensive Case

No single medication has ever simultaneously addressed testosterone decline, cancer risk, cardiovascular protection, and biological aging in this way. GLP-1 medications do it not by targeting each condition independently, but by treating the metabolic dysfunction — excess adiposity, chronic inflammation, insulin resistance — that drives all of them.

For men over 40 carrying excess weight, the 2026 data makes a compelling case that GLP-1 therapy isn't just a weight loss tool. It's a comprehensive health optimization strategy.